Protaphane

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

Insulin human

Available from:

Novo Nordisk A/S

ATC code:

A10AC01

INN (International Name):

insulin human (rDNA)

Therapeutic group:

Drogi użati fid-dijabete

Therapeutic area:

Diabetes Mellitus

Therapeutic indications:

Trattament tad-dijabete mellitus.

Product summary:

Revision: 18

Authorization status:

Awtorizzat

Authorization date:

2002-10-07

Patient Information leaflet

                                44
B. FULJETT TA' TAGĦRIF
45
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-UTENT
PROTAPHANE 40 UI/ML (UNITÀ INTERNAZZJONALI/ML) SUSPENSJONI
GĦALL-INJEZZJONI F'KUNJETT
insulina umana
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TUŻA DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK.
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anke jekk għandhom l-istess sinjali ta’
mard bħal tiegħek.
-
Jekk ikollok xi effett sekondarju kellem lit-tabib, lill-ispiżjar jew
lill-infermier tiegħek. Dan
jinkludi xi effett sekondarju possibbli li mhuwiex elenkat f’dan
il-fuljett. Ara sezzjoni 4.
1.
X’INHU PROTAPHANE U GЋALXIEX JINTUŻA
Protaphane hu insulina umana li jibda jaħdem bil-mod u li jaħdem
fit-tul.
Protaphane jintuża biex inaqqas il-livell għoli ta’ zokkor
fid-demm f’pazjenti bid-dijabete mellitus (id-
dijabete). Id-dijabete hija marda fejn il-ġisem tiegħek ma jagħmilx
biżżejjed insulina biex jikkontrolla
l-livell taz-zokkor fid-demm tiegħek
.
Il-kura b’Protaphane tgħin biex tippreveni kumplikazzjonijiet
mid-dijabete tiegħek.
Protaphane jibda jbaxxilek il-livell taz-zokkor fid-demm madwar
siegħa u nofs wara li tinjettah u l-
effett idum għal madwar 24 siegħa. Ħafna drabi Protaphane jingħata
flimkien ma’ preparazzjonijiet
tal-insulina li jaħdmu b’mod malajr.
2.
X'GĦANDEK TKUN TAF QABEL MA TUŻA PROTAPHANE
TUŻAX PROTAPHANE
►
Jekk inti allerġiku/a għall-insulina umana jew għal xi sustanza
oħra ta’ din il-mediċina, ara
sezzjoni 6.
►
Jekk qiegħed/qegħda tissusspetta bidu ta' ipogliċemija (livell baxx
ta’ zokkor fid-demm), ara
Sommarju ta’ effetti sekondarji serji u komuni ħafna f’sezzjoni
4.
►
F’pompi tal-infużjoni tal-insulina
►
Jekk l-għatu protettiv huwa laxk jew nieqes. Kull kunjett għandu
għatu protetti
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL-KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Protaphane 40 unità internazzjonali/ml suspensjoni għall-injezzjoni
f’kunjett.
Protaphane 100 unità internazzjonali/ml suspensjoni għall-injezzjoni
f’kunjett.
Protaphane Penfill 100 unità internazzjonali/ml suspensjoni
għall-injezzjoni f’skartoċċ.
Protaphane InnoLet 100 unità internazzjonali/ml suspensjoni
għall-injezzjoni f’pinna mimlija għal-
lest.
Protaphane FlexPen 100 unità internazzjonali/ml suspensjoni
għall-injezzjoni f’pinna mimlija għal-
lest.
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Protaphane f’kunjett (40 unità internazzjonali/ml)
Kunjett fih 10 ml ekwivalenti għal 400 unità internazzjonali.
Millilitru ta’ suspensjoni fih 40 unità
internazzjonali ta’ insulina isophane (NPH) umana* (ekwivalenti
għal 1.4 mg).
Protaphane f’kunjett (100 unità internazzjonali/ml)
Kunjett fih 10 ml ekwivalenti għal 1,000 unità internazzjonali.
Millilitru ta’ suspensjoni fih 100 unità
internazzjonali ta’ insulina isophane (NPH) umana* (ekwivalenti
għal 3.5 mg).
Protaphane Penfill
Skartoċċ fih 3 ml ekwivalenti għal 300 unità internazzjonali.
Millilitru ta’ suspensjoni fih 100 unità
internazzjonali ta’ insulina isophane (NPH) umana* (ekwivalenti
għal 3.5 mg).
Protaphane InnoLet/Protaphane FlexPen
Pinna mimlija għal-lest fiha 3 ml ekwivalenti għal 300 unità
internazzjonali. Millilitru ta’ suspensjoni
fih 100 unità internazzjonali ta’ insulina isophane (NPH) umana*
(ekwivalenti għal 3.5 mg).
*
L-insulina umana hija magħmula f'
_Saccharomyces cerevisiae_
permezz tat-teknoloġija tad-DNA
rikombinanti
Eċċipjent b’effett magħruf:
Protaphane fih inqas minn mmol 1 ta’ sodium (23 mg) għal kull
doża, i.e Protaphane huwa
essenzjalment ‘bla sodium’.
Għal-lista sħiħa ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Suspensjoni għall-injezzjoni.
Is-suspensjoni hija akweja, bajda u opaka.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Protaphane hu indikat
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-10-2020
Public Assessment Report Public Assessment Report Bulgarian 23-09-2014
Patient Information leaflet Patient Information leaflet Spanish 27-10-2020
Public Assessment Report Public Assessment Report Spanish 23-09-2014
Patient Information leaflet Patient Information leaflet Czech 27-10-2020
Public Assessment Report Public Assessment Report Czech 23-09-2014
Patient Information leaflet Patient Information leaflet Danish 27-10-2020
Public Assessment Report Public Assessment Report Danish 23-09-2014
Patient Information leaflet Patient Information leaflet German 27-10-2020
Public Assessment Report Public Assessment Report German 23-09-2014
Patient Information leaflet Patient Information leaflet Estonian 27-10-2020
Public Assessment Report Public Assessment Report Estonian 23-09-2014
Patient Information leaflet Patient Information leaflet Greek 27-10-2020
Public Assessment Report Public Assessment Report Greek 23-09-2014
Patient Information leaflet Patient Information leaflet English 27-10-2020
Public Assessment Report Public Assessment Report English 23-09-2014
Patient Information leaflet Patient Information leaflet French 27-10-2020
Public Assessment Report Public Assessment Report French 23-09-2014
Patient Information leaflet Patient Information leaflet Italian 27-10-2020
Public Assessment Report Public Assessment Report Italian 23-09-2014
Patient Information leaflet Patient Information leaflet Latvian 27-10-2020
Public Assessment Report Public Assessment Report Latvian 23-09-2014
Patient Information leaflet Patient Information leaflet Lithuanian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-10-2020
Public Assessment Report Public Assessment Report Lithuanian 23-09-2014
Patient Information leaflet Patient Information leaflet Hungarian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Hungarian 27-10-2020
Public Assessment Report Public Assessment Report Hungarian 23-09-2014
Patient Information leaflet Patient Information leaflet Dutch 27-10-2020
Public Assessment Report Public Assessment Report Dutch 23-09-2014
Patient Information leaflet Patient Information leaflet Polish 27-10-2020
Public Assessment Report Public Assessment Report Polish 23-09-2014
Patient Information leaflet Patient Information leaflet Portuguese 27-10-2020
Summary of Product characteristics Summary of Product characteristics Portuguese 27-10-2020
Public Assessment Report Public Assessment Report Portuguese 23-09-2014
Patient Information leaflet Patient Information leaflet Romanian 27-10-2020
Public Assessment Report Public Assessment Report Romanian 23-09-2014
Patient Information leaflet Patient Information leaflet Slovak 27-10-2020
Public Assessment Report Public Assessment Report Slovak 23-09-2014
Patient Information leaflet Patient Information leaflet Slovenian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Slovenian 27-10-2020
Public Assessment Report Public Assessment Report Slovenian 23-09-2014
Patient Information leaflet Patient Information leaflet Finnish 27-10-2020
Public Assessment Report Public Assessment Report Finnish 23-09-2014
Patient Information leaflet Patient Information leaflet Swedish 27-10-2020
Public Assessment Report Public Assessment Report Swedish 23-09-2014
Patient Information leaflet Patient Information leaflet Norwegian 27-10-2020
Summary of Product characteristics Summary of Product characteristics Norwegian 27-10-2020
Patient Information leaflet Patient Information leaflet Icelandic 27-10-2020
Summary of Product characteristics Summary of Product characteristics Icelandic 27-10-2020
Patient Information leaflet Patient Information leaflet Croatian 27-10-2020

Search alerts related to this product

View documents history